Eosinophilic esophagitis (EoE) is a chronic inflammatory condition characterized by esophageal dysfunction and dense eosinophilic infiltration of esophageal epithelium. According to clinical consensus and guidelines published in 2011, esophageal eosinophilia was classified into two entities based on response to proton pump inhibitor (PPI) administration: EoE and PPI-responsive esophageal eosinophilia (PPI-REE). We have performed a series of investigations to determine whether EoE is actually different from PPI-REE. Consistent with Western reports, more than half of our examined patients with symptomatic esophageal eosinophilia suggestive of EoE achieved histological remission with single PPI therapy. Furthermore, our comparisons of clinical, endoscopic, and histopathological findings between patients with EoE and those with PPI-REE revealed nearly no differences between them. We also compared gene expression profiles in mucosal biopsy specimens between those groups and found that microarray findings obtained from PPI-REE patients substantially overlapped with those from EoE patients, suggesting that both represent the same condition or are variations of a single disease. In addition, we have noted that more than half of EoE patients who show resistance to a PPI therapy respond to vonoprazan, a novel potassium-competitive acid blocker that has been shown to provide more potent and sustained suppression of gastric acid secretion than PPIs. Our results indicate that PPI-REE may constitute a subtype of EoE. Based on novel evidence including results obtained in our studies, the most recently updated guidelines have included responders to PPI therapy within the spectrum of EoE, abandoning the term PPI-REE.
Introduction
Eosinophilic esophagitis (EoE) is an inflammatory condition of the esophagus characterized by symptoms of esophageal dysfunction, such as dysphagia and food impaction, typical endoscopic findings, and dense esophageal eosinophilia (EE), defined by ≥ 15 eosinophils per high power field.
1,2 The condition was initially reported as a distinct clinical entity in the early 1990s, 3 then became increasingly recognized by the late 1990s, with both incidence and prevalence rapidly increasing to the present, especially in Western countries. [4] [5] [6] [7] Now, EoE has become the most common cause of dysphagia in adolescents and adults. [8] [9] [10] [11] For example, its incidence in Denmark was reported to have increased by 19.5-fold (0.13/ 1 000 000 to 2.6/100 000) from 1997 to 2012. 12 Growing numbers of studies of EoE have been published since identification of the disease, and consensus guidelines for diagnosis and management were first presented in 2007. 13 In those guidelines, the EoE diagnostic criteria include symptoms of esophageal dysfunction, 15 or more intraepithelial eosinophils/high power field in 1 or more biopsy specimens, and either normal pH monitoring of the distal esophagus or lack of response to high-dose proton pump inhibitor (PPI) medication. Those criteria were based on the assumption that only gastroesophageal reflux disease, an acid-related disorder, can respond to the acid suppressive effect of PPIs; thus, gastroesophageal reflux disease and EoE are considered to be mutually exclusive disorders. In updated guidelines published in 2011 and 2013, a new potential disease phenotype, termed PPI-responsive esophageal eosinophilia (PPI-REE), was acknowledged. 14, 15 In those recent guidelines, EE was classified into two entities based on response to PPI administration, and only patients unresponsive to PPI therapy could be diagnosed as EoE. However, studies conducted in Western countries since 2011 have found similarities in both the clinical and histopathological characteristics of EoE and PPI-REE and suggested that it is difficult to predict the response to PPI administration in patients with EE. [16] [17] [18] [19] On the other hand, the clinical characteristics and pathogenesis in Japanese populations, including similarities and differences between EoE and PPI-REE, have not been thoroughly investigated because the prevalence of EoE is very low in Asian countries. 20 In this review, we outline the current status of diagnosis and treatment of EoE in Japan mainly based on our findings and discuss the similarities and differences regarding features of EoE and PPI-REE in Japanese populations as compared with reports presented in Western countries. such as parasitic infections, drug reactions, and malignancy. EGID are subdivided into EoE and eosinophilic gastroenteritis (EGE) (Fig. 1) . 21 EoE involves only the esophagus, while EGE involves any part of the gastrointestinal tract, and it has been shown that EGE is more prevalent than EoE in Japan. 22, 23 Indeed, we encountered our first case of EoE in a 69-year-old man in 2005, which was the first Japanese case report published in English. 24 Until recently, EoE has been a very rare condition in Japan, and its epidemiology and pathophysiology have been not well documented. To determine the prevalence of EoE in patients examined by upper gastrointestinal endoscopy, we performed a prospective multicenter study in 2010, 25 in which 23 346 patients who had undergone routine upper gastrointestinal endoscopy examinations were enrolled. During the study period, four patients were finally diagnosed with EoE. From our results, the prevalence of EoE was calculated to be 17.1/100 000 (0.02%), or approximately 1 in 5000 endoscopy cases, indicating that EoE is a rare condition in Japan. However, in the 5-year period since that study, the prevalence has been found to be rapidly increasing, [26] [27] [28] [29] [30] and the most recent data reported by our related facility showed to be nearly 0.4% in Japanese subjects. 31 Next, we sought to determine the frequency of EoE in patients with esophageal symptoms and conducted a multicenter prospective study. 27 Subjects complaining of esophageal symptoms suggesting EoE and/or those with endoscopic findings suspicious of EoE obtained at outpatient clinics of 12 hospitals were prospectively enrolled. During the study period of 13 months, an upper gastrointestinal endoscopy examination was performed in 17 324 patients, of whom 349, including 319 with symptoms and 30 with no symptoms but endoscopic findings suggesting EoE, were enrolled. In the symptomatic group, eight (2.5%) were finally diagnosed with EoE, a prevalence lower than reports of Western populations. 10 Interestingly, only a single patient (0.35%) was diagnosed with EoE among those with normal endoscopic findings as compared with 18.3% (11/60) of the patients with abnormal findings, suggesting that the prevalence of symptomatic EoE patients without endoscopic abnormality is very rare.
Although patients with EoE are increasingly reported, whether EoE or EGE is more frequently diagnosed as a new case in recent findings is obscure. Our institution is a core clinical research center, and nearly all cases of EGID found in our area are introduced to our center. Figure 2 shows newly diagnosed cases with EGID examined at our institution since May 2013. EoE cases have been more frequently diagnosed than EGE, with approximately 25 newly diagnosed each year in our area. It remains unknown why the prevalence is rapidly increasing in Japan, even if increased physician and endoscopist recognition of EoE cannot be excluded. In our very recent study, inter-observer agreement regarding endoscopic diagnosis of EoE among Japanese endoscopists did not reach a clinically acceptable level, which was considered likely due to lack of experience for such diagnosis as compared with Western endoscopists, 32 though we also speculated that those results were related to the rapid decline in prevalence of Helicobacter pylori infection in recent years in Japan. 33, 34 H. pylori infection was reported to be inversely associated with presence of EoE. 35 Thus, we performed a case-control study to investigate the possible influence of H. pylori infection in EoE patients. 36 Of patients with EoE (n = 18), 22.3% were infected with H. pylori, as compared with 55.5% of age-matched and gender-matched normal controls (n = 54), and the odds ratio for EoE patients to have an H. pylori infection was calculated to be 0.22 (P < 0.05), indicating that the prevalence of H. pylori infection was significantly lower in EoE patients as compared with normal control subjects.
Clinical characteristics of eosinophilic esophagitis in Japanese populations
To clarify clinical characteristics of Japanese EoE patients, 70 cases diagnosed at our hospital were reviewed. 37 Consistent with previous reports, there was typical male predominance, as the male/female ratio was approximately 4 to 1. EoE was frequently observed in middle-aged patients, with the peak years of age in the 40s. EoE has been reported to be frequently associated with atopic disorders. 38 Consistent with that, approximately 70% of our patients had a history of allergic diseases, with allergic rhinitis Eosinophilic esophagitis in Japan most frequently observed. Taken together, baseline values for average age, male/female ratio, and personal history of allergic disease were comparable with those reported for Western populations. Furthermore, the most common symptom observed was dysphagia, whereas no patient had a history of food impaction, which is frequently observed in Western patients with EoE. Concerning endoscopic findings, linear furrows, whitish exudates, and rings were frequently observed, and at least one of those findings was seen in every case. Of them, linear furrows was the most frequently found endoscopic abnormality in our patients with EoE. In contrast, no patient showed an esophageal stricture or narrow caliber esophagus, differently from Western reports. We concluded that in Japanese patients, EoE mostly affects middle-aged men who have an allergic predisposition, similarly to Western patients. Also, dysphagia was a more common symptom than food impaction, and the complication of food bolus obstruction has not been reported in Japan, suggesting that the clinical presentation of EoE is milder than in Western populations (Table 1) .
Endoscopic characteristics of eosinophilic esophagitis
There are a number of reports of the endoscopic features of EoE, which include linear furrows, rings, whitish exudates, and stenosis (Fig. 3) . 27, 31, 37, [39] [40] [41] [42] Of those findings, we previously reported that linear furrows was the most frequently observed and reliable among characteristic endoscopic findings of EoE. 27 Those are observed as longitudinal grooves or crevices parallel to the length of the esophagus, and distinction from longitudinal mucosal breaks observed in reflux esophagitis is important for diagnosis. Therefore, we analyzed the endoscopic characteristics of linear furrows by focusing on specific locations as compared with positions of mucosal breaks in patients with reflux esophagitis. 37 Of the 70 enrolled patients with EE, 63 (90%) had linear furrows. Those were shown to occur in a radial pattern and widespread throughout the lower to upper esophagus and exclusively found in esophageal longitudinal mucosal valleys. In contrast, the vast majority of mucosal breaks in reflux esophagitis cases were located on mucosal fold ridges mainly located on the right anterior wall of the esophagus, which were findings consistent with our previous studies. [43] [44] [45] [46] In addition, increased eosinophilic infiltration was significantly more frequent in linear furrows in the valleys as compared with mucosa on adjacent ridges. These results suggested that acid reflux is not directly associated with formation of linear furrows in patients with EoE, though that may play an important role for development of EoE, based on findings showing that PPI administration is effective in more than half of patients with EE. 47 Recently, a novel endoscopic classification system termed endoscopic reference score was proposed for endoscopic assessment of five major esophageal signs of EoE, including edema, rings, exudates, furrows, and strictures, and shown to have good inter-observer and intra-observer agreement. 40, 48 We were the first to implement this scoring system for Japanese patients with EoE, and our results showed that such grading of endoscopic findings of linear furrows, white exudates, and edema is important to detect EE. 31 In contrast, other endoscopic signs, namely, cobblestone-like appearance and multiple polypoid lesions, are characterized by poor reliability and specificity (Fig. 3c) . 29, 49 Recently, we reported a novel endoscopic finding in some patients with EoE recognized as the presence of a linear longitudinal arrangement of whitish nodules with uniform intervals, such as the back of an Ankylosaurus dinosaur, which we termed Ankylosaurus back sign (ABS) (Fig. 3d) . 50 We have found this novel endoscopic finding in 16.4% of examined patients with EoE. Interestingly, all patients with ABS had PPI-REE. Although ABS was less frequent than typical endoscopic findings such as linear furrows in EE, this novel finding was closely associated with PPI-REE accompanied with reflux esophagitis. The clinical implications of ABS in patients with EE needs further investigation.
Pathogenesis of eosinophilic esophagitis in Japanese population
Eosinophilic esophagitis is recognized as an immune-mediated disorder in which food and environmental antigens simulate a Th2-type inflammatory response. 51 In 2006, Blanchard et al. initially reported a genome-wide microarray expression profile in esophageal tissue of patients with EoE. 52 Their report showed that the eotaxin-3 gene had the highest level of expression in esophagus tissues of EoE patients, while filaggrin, an epidermal differential complex protein, was significantly decreased. To investigate genetic expression profiles in esophagus tissues, we prospectively enrolled four adult Japanese patients with EoE as well as agematched healthy volunteer subjects as controls. We assessed the gene expression profiles of esophageal biopsy specimens using microarray technology and then compared the identified gene signatures with earlier findings reported in a study conducted in the USA. 53 Consistent with that previous report, IL-13-inducible and eosinophil-related genes, such as eotaxin-3 and periostin, were upregulated, and claudin-10, filaggrin, and desmoglein-1, important epithelia barrier function genes, were downregulated in the EoE group. Those results indicated that EoE patients possess a striking transcript signature involving Th2 immune response, and epithelial-related and eosinophil-specific genes, 54, 55 and also suggested that the pathogenetic mechanisms of EoE in Japan and Western countries are similar. However, measurements of the plasma concentration of these cytokines were not helpful for accurate diagnosis of EoE, because we noted large overlaps between the EoE patients and normal controls. 56, 57 Are proton pump inhibitor-responsive esophageal eosinophilia and eosinophilic esophagitis the same disease entity?
Results obtained in clinical, endoscopic, histopathological, and gene expression examinations show that PPI-REE and EoE have similar characteristics, 10, 17, 18, 58, 59 although characteristics in Japanese populations have not been fully elucidated. We compared clinical, endoscopic, and histopathological findings in 11 EoE, 16 PPI-REE, and 39 reflux esophagitis cases consecutively investigated at our hospital. 60 Consistent with previous reports, 47 more than half of the enrolled patients with EE responded to PPI treatment. The EoE patient group had a stronger atopic background including allergic comorbidities, though there were no independent clinical, endoscopic, or histopathological predictors reliably distinguishing PPI-REE from EoE. Therefore, we concluded that EoE and PPI-REE are virtually indistinguishable and proposed that they are the same or at least variations of a single disease entity.
To further evaluate the pathogenesis of EoE and PPI-REE, we used a genome-wide approach. 58, 61 Ten Japanese patients with dense EE, including four with EoE and six with PPI-REE, were enrolled, while four without eosinophilic infiltration of esophageal epithelium were used as a control group. Esophageal biopsy specimens were obtained from patients with EoE and PPI-REE prior to undergoing PPI treatment, as well as control specimens that underwent genome-wide transcriptome analysis. The majority of clinical features, including symptoms, concurrent allergic diseases, and endoscopic findings, were similar between the EoE and PPI-RRE groups. Notably, the gene expression profiles found in mucosal biopsy specimens obtained before receiving PPIs showed no major differences between them. Accordingly, our microarray findings suggested a single syndrome, calling into question the guideline position that PPI response points to existence of two distinct diseases.
14 Indeed, in agreement with our studies, the most recent guidelines have stated that adult patients showing clinical and histological response to PPI therapy are part of the EoE continuum, rather than a separate entity. 62 
Acid suppressive therapy in eosinophilic esophagitis
A recent systematic review showed that nearly half of analyzed patients with EE responded to PPI administration. 47 However, sustained efficacy in initial responders to PPI therapy was not fully examined until recently. The first long-term follow-up multicenter study was conducted in 2015 and included 75 adult patients. Those results demonstrated that all patients who had temporarily discontinued PPI therapy had symptoms and/or histological evidence of relapse. 63 On the other hand, the majority of patients maintained histological remission after at least 1 year of continuous PPI therapy with the dosage tapered to the minimum effective clinical dose. 47 In addition, CYP2C19 rapid metabolizer genotype and rhinoconjunctivitis were independent predictors of loss of response to PPI treatment; notably, dose escalation re-established responsiveness in most cases.
Vonoprazan, a novel potassium-competitive acid blocker recently approved in Japan, has shown more potent and sustained suppression of gastric acid secretion as compared with PPIs. 64 To clarify whether the stronger acid suppression by vonoprazan is more effective for patients with EE in comparison with PPI treatment, we investigated its effects in patients resistant to initial PPI therapy. 65 Four middle-aged EoE patients, most with concurrent allergic disease, were treated with vonoprazan, and three of four showed a positive response, with disappearance of both symptoms and eosinophilic infiltration during the 2-month administration period. The remaining patient did not show response and was switched to topical steroid treatment. Although our study was limited by evaluating PPI responsiveness with a standard dose, our data indicate that potassium-competitive acid blocker is a possible alternative to PPI therapy in EoE.
Conclusion
Results of studies conducted in Japan show that EoE most often affects middle-aged men who have an allergic predisposition, similarly to Western case series, although the clinical presentation in Japanese cases is milder. The pathogenetic mechanisms of EoE in Japan and Western countries are similar, although the genetic backgrounds and lifestyles, including dietary habits, are quite different. In addition, our investigations have consistently shown that clinical, endoscopic, histologic, and esophageal gene expression features of EoE and PPI-REE are virtually indistinguishable, suggesting that they are the same or at least variations of a single disease. Based on novel evidence including results obtained in our studies, the most recently updated guidelines have included responders to PPI therapy within the spectrum of EoE, abandoning the term PPI-REE. 62 Nevertheless, the underlying pathogenic mechanism of PPI response in EoE patients remains poorly understood. Studies addressing the pathophysiology of EoE responsiveness to acid suppressive therapy and the role of vonoprazan in PPIrefractory patients are warranted.
